With a new drug application for its sedative product, Aquavan, nearing submission, MGI Pharma Inc. decided to add a new drug to its development pipeline, gaining rights to a midstage thrombocytopenia drug from small biotech firm AkaRx Inc. (BioWorld Today)

With a new drug application for its sedative product, Aquavan, nearing submission, MGI Pharma Inc. decided to add a new drug to its development pipeline, gaining rights to a midstage thrombocytopenia drug from small biotech firm AkaRx Inc. (BioWorld Today)